Women’s health, CVD and hypertension

Live Webinar

Women’s health, CVD and hypertension

E-learning Modules

Launch: 8 November 2024


Hypertensive disorders of pregnancy (HDP) affect 5–10% of all pregnancies and include gestational hypertension, pre-eclampsia, chronic hypertension with superimposed pre-eclampsia, and eclampsia (Tita, 2022). Pre-eclampsia is a major cause of poor pregnancy outcomes (Magee, 2022) as well as leading to long-term negative health outcomes (Roth, 2019). Gestational hypertension is associated with long-term cardiovascular consequences. Therefore, the ISSHP addresses long-term cardiovascular risks of HDP and recommends screening patients 3 months postpartum, to monitor their blood pressure, fasting glucose levels, and lipid profiles (Magee, 2022). Despite these recommendations, HCPs have insufficient knowledge about the increased cardiovascular risks after HDP (Roth, 2019). During the transition to menopause, women’s susceptibility to CVD significantly increases and remains high post-menopause (Okeahialam, 2022). This increased risk is mainly due to accelerated vascular ageing (Nair, 2021), which plays a crucial role in the development of hypertension and atherosclerosis. The prevalence of heart failure with preserved ejection fraction (HFpEF) also increases following menopause, with post-menopausal women comprising the majority of HFpEF patients (Barton, 2020). Patient–healthcare professional engagement presents a valuable opportunity to assess and counsel women about their cardiovascular risk profile (Hodis, 2016). The North American Menopause Society recommends hormone replacement therapy for reducing vasomotor symptoms within ten years of menopause onset in women aged younger than 60 with no contraindications (The Hormone Therapy Position Statement of the North American Menopause Society Advisory Panel, 2022). This live webinar will focus on HDP and menopausal CVD risk and discuss the guidelines for monitoring for cardiovascular risk and management/treatment.

Learning Objectives

After attending this webinar, participants will be able to:

Target Audience

Clinicians (including cardiologists, internists, and general practitioners), nurse practitioners and other HCPs who manage patients with hypertension and heart failure. Some content of interest to gynaecologists, midwives, nurses involved in women’s health care.


English with voice-over into Russian and Chinese


Stefano Taddei

Stefano Taddei

Department of Clinical and Experimental Medicine, University of Pisa
Pisa, Italy


Rosa Maria Bruno

Rosa Maria Bruno

Paris, France


Save the Date

Download Save the Date


· Stefano Taddei ·

Stefano Taddei is Full Professor of Internal Medicine, currently working as Director of the Hypertension Unit at the Department of Clinical and Experimental Medicine of the University of Pisa, Italy. He is a fellow of the European Society of Cardiology, member of the European, International and American Society of Hypertension, the European Society of Clinical Investigation and the High Blood Pressure Council of the American Heart Association. Professor Taddei is an editorial board member for numerous international and national scientific journals, Hypertension, Journal of Hypertension, Journal of Cardiovascular Pharmacology, Blood Pressure and he is Deputy Editor of the European Heart Journal. His main research area is the neuro-humoral control of peripheral peripheral arterial circulation in essential and secondary hypertension, with particular emphasis on adrenergic mechanisms, non-adrenergic neurotransmitters, the circulating and vascular renin-angiotensin system and endothelial function. Professor Taddei has participated in numerous clinical studies and is the authors of more than 400 original papers, reviews editorials and book chapters in international scientific journals (H index: 74; Impact Factor: >3000).

· Martin O. Savage ·

Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.  His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 61 countries and has published 472 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.